Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection (CASPR)

January 2, 2026 updated by: University Hospital, Strasbourg, France

Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained.

The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections.

The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

260

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France
        • Principal Investigator:
          • Martin MARTINOT, MD
        • Sub-Investigator:
          • Julien GODET, Statistician
        • Contact:
        • Principal Investigator:
          • Stéphane KLEIN, MD
        • Sub-Investigator:
          • Cécile ROND-OUSTAU, MD
        • Principal Investigator:
          • Aurélie BALDOLI, MD
        • Principal Investigator:
          • Clément THEIS, MD
        • Principal Investigator:
          • Kevin BOUILLER, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

- Adult patient at the time of surgery for infection with a probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria

Description

Inclusion Criteria:

  • Adult patient (aged 18 years or older) at the time of surgery for infection
  • Probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria
  • Patient operated on in one of the associated centers between 2013 and 2024

Exclusion Criteria:

  • Patient who underwent joint resection or amputation
  • Patient who was treated with suppressive antibiotic therapy (defined as antibiotic treatment lasting more than 6 months) which was decided upon prior to surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Therapeutic success of the medical-surgical strategy
Time Frame: One year after the end of antibiotic treatment
Therapeutic success of the medical-surgical strategy defined as: patient showing no clinical signs of infection, no need for repeat surgery one year after the end of antibiotic treatment, and no repeat antibiotic treatment.
One year after the end of antibiotic treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 21, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 21, 2026

Study Registration Dates

First Submitted

January 2, 2026

First Submitted That Met QC Criteria

January 2, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 2, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9536

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Streptococcus Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe